S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 1063-1073

  Millan, Mark J ^a,b   Dekeyne, Anne ^a   Rivet, Jean Michel ^a   Dubuffet, Thierry ^a   Lavielle, Gilbert ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 4 (4 CHLOROPHENYL) 1 (1H INDOL 3 YLMETHYL)PIPERIDIN 4 OL; DOPAMINE 3 RECEPTOR BLOCKING AGENT; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H-BENZOPYRANO[3,4 C]PYRROLE 2 YL)BUTYL] 4 PHENYLBENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG POTENCY; EVOKED RESPONSE; HYPOPHAGIA; HYPOTHERMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN RELEASE; RAT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION;

ANIMALS; BEHAVIOR, ANIMAL; BENZOPYRANS; BODY TEMPERATURE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRAPYRAMIDAL TRACTS; INDOLES; MALE; MICE; MOTOR ACTIVITY; OXAZINES; PIPERIDINES; PSYCHOTROPIC DRUGS; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SULFONES; TETRAHYDRONAPHTHALENES;

EID: 0034047204     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. 3 receptor ligand 7-OH-DPAT on male rat ejaculatory behavior. Pharmacol Biochem Behav 51:545-547.
3. Argiolas A and Melis MR (1997) The neuropharmacology of yawning. Eur J Pharmacol 343:1-16.
4. 3 receptor antagonists, (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287:187-197.
5. 2 receptors. Nature (Lond) 377:424-428.
6. 1 activation. Pharmacol Biochem Behav 60:313-319.
7. 3 receptor agonists. Neuropharmacology 38:1389-1396.
8. 3 knock-out and wild-type mice. Neuropharmacology 38:555-565.
9. 2 receptor mRNA. Brain Res 564:203-219.
10. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283: 1256-1263.
11. 3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 35:285-294.
12. Cunningham-Owens DC (1996) Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 51:895-930.
13. 2 receptors. Eur J Pharmacol 394:47-50.
14. 3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res 748:83-91.
15. 3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons. Eur J Pharmacol 335:37-42.
16. 3H]-spiperone binding. Naunyn-Schmiedeberg's Arch Pharmacol 358:342-350.
17. 2C receptor. Neuropsychopharmacology 21:S82-S90.
18. Gorelick DA and Balster RL (1995) Phencyclidine (PCP), in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1767-1776, Raven Press, New York.
19. 2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
20. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch Gen Psychiatry 54:225-231.
21. 3 receptor antagonist. CNS Drug Rev 4:42-53.
22. 3H]PD128,907. Psychopharmacology 128:240-247.
23. Harrison PJ (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Br J Psychiatry 174:12-22.
24. Jordan BA and Devi L (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature (Lond) 399:697-700.
25. 3 receptors. Neuroscience 91:911-924.
26. Keks NA (1996.) Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 94:18-24.
27. 2 dopamine-receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
28. Kerwin H and Owen M (1999) Genetics of novel therapeutic targets in schizophrenia. Br J Psychiatry 174:1-4.
29. 2 receptors in the shell of the nucleus accumbens; turning behaviour. Eur J Pharmacol 308:235-241.
30. 4 receptor. J Med Chem 39:1941-1942.
31. 3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav 52:503-508.
32. 2 dopamine receptors produces additive anorectic effects. Fundam Clin Pharmacol 5:481-490.
33. Leibowitz SF (1980) Neurochemical systems of the hypothalamus in control of feeding and drinking behaviour and water-electrolyte secretion, in Handbook of the Hypothalamus (Morgane PJ and Panksepp J eds) pp 299-437, Marcel Dekker, Inc., New York.
34. Maggio R, Barbier P, Colelli A, Salvadori F, Demontis G and Corsini GU (1999) G protein-linked receptors: Pharmacological evidence for the formation of heterodimers. J Pharmacol Exp Ther 291:251-257.
35. Martin P, Waters N, Waters S, Carlsson A and Carlsson ML (1997) MK-801-induced hyperlocomotion: Differential effects of MDL 100,907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107-116.
36. Melis MR, Argiolas A and Gessa GL (1987) Apomorphine-induced penile erection and yawning: Site of action in brain. Brain Res 415:98-104.
37. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432.
38. 2-adrenergic receptors: II. Functional profile and a multiparametric comparison to haloperidol, clozapine and 11 other antipsychotic agents. J Pharmacol Exp Ther 292:54-66.
39. 3-receptors: I. Receptional, electrophysiological, and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062.
40. 4 receptors: An in vitro and in vivo comparison to L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo [2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287: 167-186.
41. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
42. 1A agonist properties. II: Functional profile in comparison to clozapine and haloperidol J Pharmacol Exp Ther 286:1356-1373.
43. Missale C, Nash SR, Robinson SW, Jaber M and Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
44. Moore NA (1999) Behavioural pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 174:5-11.
45. 3 receptor. Bioorg Med Chem Lett 6:403-408.
46. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191.
47. 3 receptors. Eur J Pharmacol 366:293-300.
48. 3 receptor agonist. Nature (Lond) 400:371-375.
49. 3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366.
50. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19:4627-4633.
51. 3 dopamine receptor in cellular and organismal function. Psychopharmacology 135:1-16.
52. Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A and Kitai ST (1992) Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 89:10178-10182.
53. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779:58-74.
54. 1-adrenoceptor antagonism. J Clin Psychopharmacol 15:S11-S18.
55. Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21-36.
56. 3 receptors? Biol Pharmacol 9:445-455.
57. 3 receptor-selective agonists and antagonists. Synapse 31:210-215.
58. 2 receptors. Neuron 19:837-848.